Exscientia, a leading AI drug discovery company, has set its sights on becoming the first to design clinically validated drugs using AI. The company’s presentation deck reveals a robust pipeline of small molecule drugs in various stages of development, including a Phase I clinical trial.
The company’s proprietary Centaur Chemist™ platform utilises AI to design novel drug molecules, a process that significantly reduces the time and cost associated with traditional drug discovery. This platform has already yielded two drugs in less than 12 months, a testament to its effectiveness.
Exscientia’s business model is twofold. It collaborates with pharmaceutical companies, sharing the risks and rewards of drug discovery, while also developing its own in-house drug pipeline. This dual approach offers both stability and potential for high returns.
In terms of financials, Exscientia has secured £109 million in Series C funding, with the company valued at £1.2 billion. It plans to use these funds to further develop its AI platform and expand its drug pipeline.
Despite the promising outlook, Exscientia faces challenges. These include the unproven nature of AI in drug discovery, the long timeframes associated with drug development, and competition from other AI drug discovery companies.
Go to source article: https://axial.substack.com/p/deck-review-with-exscientia